Indicadores de Prod. Científica
Publicaciones Científicas
Patentes
Gaceta Electrónica de I+D
Ayuda
Descripción de Contenidos
Uso de la Página
Sugerencias y Propuestas
Convocatorias y
Documentos
Convocatorias y Ayudas de I+D
Documentos e Informes
Normativa
Recursos Investigación
Centros de Investigación
Grupos de Investigación
Investigadores
Equipamientos de I+D
Comités Eticos
Actividad Investigadora
Proyectos de Investigación
Ensayos Clínicos
Indicadores
Nuevos Proyectos
Resultados Investigación
Indicadores Prod. Científica
Publicaciones Científicas
Patentes
Gaceta Electrónica de I+D
Formación
Apoyo Metodológico
Oferta Formativa
Bibliografía Seleccionada
Recursos Metodológicos
Recursos Bibliográficos
Otros Recursos
Museo de la Sanidad
Enlaces de Interés
Ofertas de Trabajo
y Colaboración
Noticias
Eventos
Prostacyclin: its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism

Titulo

Prostacyclin: its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism 

Revista

BLOOD PRESSURE 

Año

1999 

Volumen

Página Inicial

279 

Página Final

284 

Autores

Rodriguez-Garcia, JL; Villa, E; Serrano, M; Gallardo, J; Garcia-Robles, R

Centros Participantes

Hosp Gen La Mancha Ctr, Med Interna Serv, ES-13600 Ciudad Real, Spain; Hosp Ramon y Cajal, Dept Endocrinol, E-28034 Madrid, Spain

Resumen

Angiotensin-converting enzyme inhibitors (ACEI) block degradation of bradykinin, and bradykinin stimulates prostacyclin synthesis. Therefore, we set out to determine whether the effects of ACE inhibitors on prostaglandin production in essential hypertensive patients are class effects or are dependent on ACE inhibitor structure. In addition, we studied whether hypertensives show an impaired capacity to synthesize vasodilator prostaglandins. To address these questions, we compared the effects of captopril (sulfhydryl-containing inhibitor), enalapril and ramipril (carboxyl-containing inhibitors) and fosinopril (phosphoryl-containing inhibitor) on blood pressure and urinary excretion of 6-keto-prostaglandin (PG) F1-alpha (the breakdown product of prostacyclin) in 44 mild-to-moderate essential hypertensive subjects before and 8 weeks after administration of an ACEI. We also studied prostacyclin excretion in 15 normotensive healthy controls. Levels of urinary 6-keto-PGF1-alpha (pg/ml) were measured by specific radioimmunoassay. Hypertensive subjects showed a lower excretion of 6-keto-PGF1-alpha than normotensive controls (212 +/- 147 vs 353 +/- 98 pg/ml, p < 0.001). All ACEI induced a significant decrease in MAP and increased the rate of excretion of the prostacyclin metabolite: C, 211 +/- 200 to 338 +/- 250 pg/ml, p < 0.05; E, 202 +/- 133 to 296 +/- 207 pg/ml, p < 0.05; R, 205 +/- 127 to 342 +/- 211 pg/ml, p < 0.05; F, 235 +/- 128 to 347 +/- 241 pg/ml, p < 0.05. In hypertensives (n = 44) the decrease in blood pressure correlated negatively with the rise in 6-keto-PGF1-alpha excretion (r= -0.51, p < 0.001). These data suggest that impaired prostacyclin biosynthesis in hypertensive patients could account for haemodynamic changes leading to the hypertensive state. Moreover, the hypotensive mechanisms of ACEI may be mediated by an increase in prostacyclin production; this effect seems to be class-dependent.
Datos adjuntos
Tipo de contenido: PublicacionesCientificas
Creado el 11/05/2017 13:41  por Cuenta del sistema 
Última modificación realizada el 11/05/2017 13:41  por Cuenta del sistema